Review
Immunology
Roberto Caporali, Yannick Allanore, Rieke Alten, Bernard Combe, Patrick Durez, Florenzo Iannone, Mike T. Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park, Dae Hyun Yoo
Summary: The study found that CT-P13 SC has more advantages compared to infliximab in treating patients with RA, demonstrating better efficacy and safety. Comparison with historical data also showed that CT-P13 SC has certain advantages over adalimumab/etanercept in terms of safety and efficacy.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2021)
Article
Immunology
Jing-Wen Chen, Guo-Shu Deng, Wen-Shuang Zhang, Ming-Ying Zhang, Tong Guan, Qiang Xu
Summary: This study reported the first successful case of a 60-year-old HIV-positive woman with difficult-to-treat RA who was treated with ADA therapy. It was found that adalimumab is a safe option for patients with RA-HIV and may slow down the progression of HIV infection. Furthermore, HAART therapy has the potential to reduce joint pain and fatigue in patients with difficult-to-treat RA.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Liana Barenbrug, Maarten te Groen, Frank Hoentjen, Joris van Drongelen, Juul M. P. A. van den Reek, Irma Joosten, Elke M. G. J. de Jong, Renate G. van der Molen
Summary: The use of anti-TNF alpha agents during pregnancy in women with immune mediated inflammatory diseases, such as IBD, RA, and PS, is associated with an increased risk of preterm birth and infections in newborns, particularly for women with IBD. However, there was no increased risk for adverse pregnancy outcomes in women with RA and PS. Vaccination in children exposed to anti-TNF alpha seems to be safe and important in reducing the risk of infections.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Immunology
Audrey Paoletti, Bineta Ly, Samuel Bitoun, Gaetane Nocturne, Elodie Riviere, Jessica J. Manson, Andrea Matucci, Marc Pallardy, Niek De Vries, Xavier Mariette
Summary: This longitudinal study demonstrates that ADA but not ETA is able to restore the M2-like polarization of monocytes that is defective in RA.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Farhad Gharibdoost, Amir-Hossein Salari, Mansour Salesi, Faegheh Ebrahimi Chaharom, Peyman Mottaghi, Mansour Hosseini, Maryam Sahebari, Mohammadali Nazarinia, Zahra Mirfeizi, Mohammadreza Shakibi, Hamidreza Moussavi, Mansour Karimifar, Karim Mowla, Hadi Karimzadeh, Nassim Anjidani, Ahmadreza Jamshidi
Summary: This study aimed to evaluate the safety and effectiveness of biosimilar etanercept in patients with RA, AS, and PsA. The results demonstrated the real-world safety and effectiveness of biosimilar etanercept in patients with RA, PsA, and AS.
ADVANCES IN THERAPY
(2021)
Article
Medicine, General & Internal
Yusuke Yoshimura, Shun Watanabe, Masayuki Yamanouchi, Daisuke Ikuma, Hiroki Mizuno, Akinari Sekine, Eiko Hasegawa, Tatsuya Suwabe, Kei Kono, Keiichi Kinowaki, Kenichi Ohashi, Yoshifumi Ubara, Naoki Sawa
Summary: We encountered an 86-year-old Japanese woman with proteinuria, hematuria, decreased renal function, and elevated MPO-ANCA levels during treatment of rheumatoid arthritis. Kidney biopsy showed pauci-immune necrotizing glomerulonephritis and ANCA-associated vasculitis was diagnosed. Treatment with tocilizumab resulted in improvement of renal findings and normalization of disease activity and serum ANCA levels.
Article
Medicine, General & Internal
Daniela Anghel, Carmen Adella Sirbu, Oana-Georgiana Petrache, Daniela Opris-Belinski, Maria Magdalena Negru, Violeta-Claudia Bojinca, Cristina Florentina Plesa, Florentina Ionita Radu
Summary: Videocapillaroscopy is a simple, non-invasive investigation used to study nailfold capillaries. It is commonly used for patients with Raynaud's phenomenon and systemic sclerosis, but can also be used for patients with suspected microcirculation alterations. The study aimed to identify nailfold videocapillaroscopic abnormalities in rheumatoid arthritis and psoriatic arthritis patients and analyze their correlation with 12 months of anti-TNF-α therapy. The findings showed significant improvements in capillary density, dilated and giant capillaries, elongated capillaries, and angiogenesis after 12 months of treatment, with no avascular areas found.
Review
Pharmacology & Pharmacy
Rui Hu, Tao Yuan, Hui Wang, Jianglin Zhao, Liya Shi, Quankai Li, Chunmei Zhu, Na Su, Shengzhao Zhang
Summary: This meta-analysis found that etanercept biosimilars were more effective than reference biologics (Enbrel) in terms of ACR50 response rate for treating active rheumatoid arthritis, while other outcomes related to efficacy, safety, and immunogenicity were comparable between etanercept biosimilars and the originator.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Rheumatology
Benjamin Sornrung Naovarat, Gloria Salazar, Mariko Ishimori, Francis M. Williams, John D. Reveille
Summary: The study suggests that biological therapy, particularly anti-TNF agents, is safe and well tolerated in HIV-positive rheumatology patients, even over several years.
Article
Biochemistry & Molecular Biology
Tomasz Wysocki, Agnieszka Paradowska-Gorycka
Summary: Rheumatoid arthritis is a common inflammatory arthritis in which tumor necrosis factor plays a key role. However, there is variation in response to TNF-targeting drugs, which may be influenced by genetic factors. The field of pharmacogenomics offers potential for developing novel prognostic tools.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pediatrics
Lili Ye, Yingying Jin, Hua Huang, Fei Ding, Xuemei Xu, Chenxi Liu, Shengfang Bao, Jing Wu, Yanliang Jin
Summary: This study explored the role of DKK-1 and SOST in the pathogenesis of JIA. It was found that plasma levels of DKK-1 were significantly higher in JIA patients, especially in those with HLA-B27 positivity. After treatment, DKK-1 levels decreased significantly. However, there was no significant change in SOST levels among different JIA subtypes, before and after treatment, and healthy controls.
PEDIATRIC RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Alexander Vugler, James O'Connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Elizabeth Hickford, Alexander Verbitsky, Xiaoyou Ying, Markus Rehberg, Bruce Carrington, Mark Merriman, Andrew Moss, Jean-Marie Nicholas, Phil Stanley, Sara Wright, Tim Bourne, Yann Foricher, Daniel Brookings, Helen Horsley, Matthias Herrmann, Srinivas Rao, Markus Kohlmann, Peter Florian
Summary: This article reports the discovery and development of a potent small molecule inhibitor of TNF, SAR441566, which has shown potential as a treatment option for chronic autoimmune diseases. By stabilizing an asymmetrical form of TNF and compromising its functions, SAR441566 offers a promising alternative to established biologic drugs targeting TNF.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Anna Szeremeta, Agnieszka Jura-Poltorak, Aleksandra Zon-Giebel, Krystyna Olczyk, Katarzyna Komosinska-Vassev
Summary: Tumor necrosis factor alpha inhibitor (TNF alpha I) therapy, combined with methotrexate, can effectively inhibit radiographic progression and improve physical function and quality of life among patients with rheumatoid arthritis (RA). The study evaluated the effect of 15-month anti-TNF-alpha therapy on cartilage turnover markers in female RA patients and found significant changes in serum levels of biochemical markers and ratios. Baseline COMP levels were associated with disease activity and could be used as a predictor. The C2C/PIICP ratio showed promising potential as a biomarker for monitoring the effectiveness of anti-TNF-alpha treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Atefeh Fakharian, Saghar Barati, Maryam Mirenayat, Mitra Rezaei, Sara Haseli, Pooria Torkaman, Sahar Yousefian, Alireza Dastan, Hamidreza Jamaati, Farzaneh Dastan
Summary: The use of adalimumab in combination with remdesivir and dexamethasone did not show significant benefits in treating severe COVID-19 cases, as demonstrated by similar mortality rates, mechanical ventilation requirements, and lengths of hospital and ICU stay between the intervention and control groups.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Immunology
XiaoQin Lu, Rui Hu, Lin Peng, MengSi Liu, Zhen Sun
Summary: "Seven biosimilars of adalimumab approved for rheumatoid arthritis treatment by FDA and/or EMA have shown similar efficacy, safety, and immunogenicity to adalimumab, with switching trials indicating no significant impact on these factors."
FRONTIERS IN IMMUNOLOGY
(2021)
Letter
Rheumatology
Ennio Giulio Favalli, Francesca Ingegnoli, Rolando Cimaz, Roberto Caporali
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Letter
Rheumatology
Serena Bugatti, Ludovico De Stefano, Ennio Giulio Favalli, Roberto Caporali, Carlomaurizio Montecucco
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Letter
Rheumatology
Ennio Giulio Favalli, Orazio De Lucia, Martina Biggioggero, Nicoletta Del Papa, Roberto Caporali
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
Piercarlo Sarzi-Puttini, Daniela Marotto, Roberto Caporali, Carlo Maurizio Montecucco, Ennio Giulio Favalli, Franco Franceschini, Michela Fredi, Silvia Balduzzi, Chiara Bazzani, Sara Bongiovanni, Valeria Giorgi, Alberto Batticciotto, Antonella Cappelli, Patrizia Balzarini, Lorenzo Dagna, Silvia Sartorelli, Viviana Ravagnani, Silvia Tamanini, Sonia Farah, Paola Faggioli, Laura Castelnovo, Alfredo Maria Lurati, Massimo Galli, Fausto Salaffi
Summary: The study found that rheumatic patients have a similar risk of contracting COVID-19 as the general population, but age, disease duration, and number of co-morbidities are associated with an increased risk of a severe form of the disease. Immunosuppressants drugs seem to not effectively represent a risk factor for COVID-19.
JOURNAL OF AUTOIMMUNITY
(2021)
Letter
Rheumatology
Francesca Ingegnoli, Gilberto Cincinelli, Angela Flavia Luppino, Ennio Giulio Favalli, Annalisa Orenti, Patrizia Boracchi, Roberto Caporali
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Review
Immunology
Ennio Giulio Favalli, Gabriella Maioli, Martina Biggioggero, Roberto Caporali
Summary: The COVID-19 pandemic poses challenges for managing patients with rheumatoid arthritis (RA) due to their increased susceptibility to infection events. Disease-modifying anti-rheumatic drugs (DMARDs) have potential effects on patients' vulnerability to COVID-19, and international guidelines emphasize the importance of focusing on RA patients in this context.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Maria Gabriella Raimondo, Martina Biggioggero, Lavinia Agra Coletto, Andreas Ramming, Roberto Caporali, Ennio Giulio Favalli
Summary: Rheumatoid arthritis is a chronic autoimmune disease with a modified natural course due to the development of new therapeutic approaches. Filgotinib, a Janus kinase1 selective inhibitor, has shown comparable clinical efficacy to biologic treatments for active RA with an acceptable safety profile. Real-life data and head-to-head clinical trials are needed to confirm its efficacy and safety.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Meeting Abstract
Rheumatology
S. D'angelo, E. Tirri, A. M. Giardino, M. Matucci-Cerinic, L. Dagna, L. Santo, F. Ciccia, B. Frediani, M. Govoni, F. Bobbio Pallavicini, R. D. Grembiale, A. Delle Sedie, S. Cercone, R. Mule, F. P. Cantatore, R. Foti, E. Gremese, R. Perricone, F. Salaffi, O. Viapiana, A. Cauli, R. Giacomelli, L. Arcarese, G. Guggino, R. Russo, D. Capocotta, F. Nacci, M. G. Anelli, V. Picerno, F. Iannone
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Letter
Rheumatology
Ludovico De Stefano, Francesca Bobbio-Pallavicini, Carlomaurizio Montecucco, Serena Bugatti
Letter
Rheumatology
A. Biglia, E. Bozzalla Cassione, G. Zanframundo, L. Cavagna, V Morandi, F. Bobbio Pallavicini, A. Valentini, G. Cavenaghi, C. Montecucco
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2022)
Article
Rheumatology
Serena Bugatti, Ludovico De Stefano, Bernardo D'Onofrio, Andrea Nicrosini, Eleonora Mauric, Michele di Lernia, Garifallia Sakellariou, Ennio Giulio Favalli, Antonio Manzo, Roberto Caporali, Carlomaurizio Montecucco
Summary: This study found that in the early stages of rheumatoid arthritis, particularly in patients who test positive for autoantibodies, inflammatory markers are directly correlated with the Patient Global Assessment. However, in patients with established rheumatoid arthritis, there is no independent correlation between inflammatory markers and the Patient Global Assessment, regardless of disease activity and autoantibody status.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Pharmacology & Pharmacy
Gabriella Maioli, Roberto Caporali, Ennio Giulio Favalli
Summary: This article discusses the role of the IL-6 pathway in the pathogenesis of rheumatoid arthritis and the pharmacologic properties of the IL-6 inhibitor sarilumab. Clinical trials have confirmed the efficacy and safety of sarilumab in treating RA, making it a potential alternative for patients intolerant to conventional disease-modifying drugs.
EXPERT OPINION ON DRUG DISCOVERY
(2022)
Article
Medicine, General & Internal
Salvatore D'Angelo, Enrico Tirri, Angela Maria Giardino, Marco Mattucci-Cerinic, Lorenzo Dagna, Leonardo Santo, Francesco Ciccia, Bruno Frediani, Marcello Govoni, Francesca Bobbio Pallavicini, Rosa Daniela Grembiale, Andrea Delle Sedie, Rita Mule, Francesco Paolo Cantatore, Rosario Foti, Elisa Gremese, Paola Conigliaro, Fausto Salaffi, Ombretta Viapiana, Alberto Cauli, Roberto Giacomelli, Luisa Arcarese, Giuliana Guggino, Romualdo Russo, Amy Puenpatom, Domenico Capocotta, Francesca Nacci, Maria Grazia Anelli, Valentina Picerno, Corrado Binetti, Florenzo Iannone
Summary: This prospective observational study collected data from rheumatology clinics in Italy and found that golimumab (GLM) as a second anti-TNF drug is effective in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). GLM improved disease activity and quality of life in these patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E. G. Favalli, R. Caporali
Summary: The objective of this study was to evaluate the survival rates of biological disease-modifying anti-rheumatic drugs (bDMARDs) in patients with psoriatic arthritis (PsA), comparing tumor necrosis factor inhibitors (TNFi) and non-TNFi retention rates. The study found that the TNFi group had a younger age at the start of therapy and a lower proportion of patients with skin psoriasis. Survival analysis showed no significant differences between TNFi and non-TNFi groups. Cox regression analysis identified fibromyalgia as a predictor of drug failure and first-line bDMARDs as a protective factor.
Article
Rheumatology
E. Marasco, M. Mussa, F. Motta, F. Bobbio-Pallavicini, R. Maserati, C. Montecucco, L. Bogliolo
Summary: The prevalence of osteoporosis in people living with HIV is about three times higher than in the general population, and bisphosphonates are the only class of antiresorptive drugs proven to be safe and effective in HIV patients. Denosumab may be a safe and effective treatment approach for osteoporosis in patients with HIV.